Cryogenic Solutions Inc. (CYGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Cryogenic Solutions Inc. (CYGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Graham Marshman who wrote (3517)	1/19/1999 6:19:00 PM
From: Hogger	Read Replies (1) of 4028

Graham, Probably Dr. Graystoned would not understand what it says, and certainly not what it means ... however, for the more learned, here is the text of the release and the link: go2net.newsalert.com Intracellular Synthesis of Telomeric Repeat Appears Lethal To Malignant Cells Business Wire - January 19, 1999 15:19 HOUSTON--(BUSINESS WIRE)--Jan. 19, 1999--Cryogenic Solutions Inc. (OTC BB:CYGS)announced the positive results of its experimental expression of the (TTAGGG)n oligonucleotide sequence in HeLa cells. As expected, intracellular expression of the (TTAGGG)n oligo appeared to select against malignant cells which expressed the telomeric repeat whereas HeLa cultures transfected to express a control sequence of the same length continue to thrive. The company's ssDNA expression vector uses viral encoded genes to produce intracellular oligonucleotide sequences of any desired composition, which effectively avoids some of the major hurdles associated with antisense delivery. The vector can be described as a custom designed biological factory that synthesizes single-stranded DNA inside living cells. The researchers are able to program the sequences of ssDNA to be manufactured once the vector has entered a cell. It is anticipated that the ssDNA expression vector will soon allow biomedical research to graduate from cell cultures to live animal studies, especially those involving antisense technologies and therapies. The (TTAGGG)n sequence is one of many that have been shown in vitro to kill cancer cells. A series of subsequent in vivo studies are planned to demonstrate that the patented product performs as expected with a variety of catalogued sequences. CONTACT: Cryogenic Solutions Inc., Houston Dell Gibson, 713/780-1399

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next